• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

定义前庭神经鞘瘤具有临床意义的肿瘤大小,以指导等待观察管理期间显微手术的时机:超越最小可检测生长。

Defining clinically significant tumor size in vestibular schwannoma to inform timing of microsurgery during wait-and-scan management: moving beyond minimum detectable growth.

作者信息

Macielak Robert J, Wallerius Katherine P, Lawlor Skye K, Lohse Christine M, Marinelli John P, Neff Brian A, Van Gompel Jamie J, Driscoll Colin L W, Link Michael J, Carlson Matthew L

机构信息

1Department of Otolaryngology-Head and Neck Surgery.

2Department of Quantitative Health Sciences; and.

出版信息

J Neurosurg. 2021 Oct 15;136(5):1289-1297. doi: 10.3171/2021.4.JNS21465. Print 2022 May 1.

DOI:10.3171/2021.4.JNS21465
PMID:34653971
Abstract

OBJECTIVE

Detection of vestibular schwannoma (VS) growth during observation leads to definitive treatment at most centers globally. Although ≥ 2 mm represents an established benchmark of tumor growth on serial MRI studies, 2 mm of linear tumor growth is unlikely to significantly alter microsurgical outcomes. The objective of the current work was to ascertain where the magnitude of change in clinical outcome is the greatest based on size.

METHODS

A single-institution retrospective review of a consecutive series of patients with sporadic VS who underwent microsurgical resection between January 2000 and May 2020 was performed. Preoperative tumor size cutpoints were defined in 1-mm increments and used to identify optimal size thresholds for three primary outcomes: 1) the ability to achieve gross-total resection (GTR); 2) maintenance of normal House-Brackmann (HB) grade I facial nerve function; and 3) preservation of serviceable hearing (American Academy of Otolaryngology-Head and Neck Surgery class A/B). Optimal size thresholds were obtained by maximizing c-indices from logistic regression models.

RESULTS

Of 603 patients meeting inclusion criteria, 502 (83%) had tumors with cerebellopontine angle (CPA) extension. CPA tumor size was significantly associated with achieving GTR, postoperative HB grade I facial nerve function, and maintenance of serviceable hearing (all p < 0.001). The optimal tumor size threshold to distinguish between GTR and less than GTR was 17 mm of CPA extension (c-index 0.73). In the immediate postoperative period, the size threshold between HB grade I and HB grade > I was 17 mm of CPA extension (c-index 0.65). At the most recent evaluation, the size threshold between HB grade I and HB grade > I was 23 mm (c-index 0.68) and between class A/B and C/D hearing was 18 mm (c-index 0.68). Tumors within 3 mm of the 17-mm CPA threshold displayed similarly strong c-indices. Among purely intracanalicular tumors, linear size was not found to portend worse outcomes for all measures.

CONCLUSIONS

The probability of incurring less optimal microsurgical outcomes begins to significantly increase at 14-20 mm of CPA extension. Although many factors ultimately influence decision-making, when considering timing of microsurgical resection, using a size threshold range as depicted in this study offers an evidence-based approach that moves beyond reflexively recommending treatment for all tumors after detecting ≥ 2 mm of tumor growth on serial MRI studies.

摘要

目的

在全球大多数中心,观察期间检测前庭神经鞘瘤(VS)的生长情况会促使进行确定性治疗。尽管≥2mm是连续MRI研究中已确立的肿瘤生长基准,但2mm的线性肿瘤生长不太可能显著改变显微手术结果。当前研究的目的是确定基于肿瘤大小,临床结果变化幅度最大的临界点。

方法

对2000年1月至2020年5月期间接受显微手术切除的一系列散发性VS患者进行单机构回顾性研究。术前肿瘤大小切点以1mm的增量定义,并用于确定三个主要结果的最佳大小阈值:1)实现全切除(GTR)的能力;2)维持House-Brackmann(HB)I级面神经功能正常;3)保留有用听力(美国耳鼻咽喉头颈外科学会A/B级)。通过最大化逻辑回归模型的c指数获得最佳大小阈值。

结果

在603例符合纳入标准的患者中,502例(83%)的肿瘤有小脑脑桥角(CPA)扩展。CPA肿瘤大小与实现GTR、术后HB I级面神经功能以及保留有用听力显著相关(所有p<0.001)。区分GTR和非GTR的最佳肿瘤大小阈值是CPA扩展17mm(c指数0.73)。在术后即刻,HB I级和HB>I级之间的大小阈值是CPA扩展17mm(c指数0.65)。在最近一次评估时,HB I级和HB>I级之间的大小阈值是23mm(c指数0.68),A/B级和C/D级听力之间的大小阈值是18mm(c指数0.68)。在距17mm CPA阈值3mm范围内的肿瘤显示出类似的强c指数。在纯内听道肿瘤中,未发现线性大小预示所有指标的预后更差。

结论

当CPA扩展达到14 - 20mm时,显微手术结果不太理想的可能性开始显著增加。尽管许多因素最终会影响决策,但在考虑显微手术切除时机时,使用本研究中描述的大小阈值范围提供了一种基于证据的方法,超越了在连续MRI研究中检测到肿瘤生长≥2mm后就 reflexively 推荐对所有肿瘤进行治疗的做法。

相似文献

1
Defining clinically significant tumor size in vestibular schwannoma to inform timing of microsurgery during wait-and-scan management: moving beyond minimum detectable growth.定义前庭神经鞘瘤具有临床意义的肿瘤大小,以指导等待观察管理期间显微手术的时机:超越最小可检测生长。
J Neurosurg. 2021 Oct 15;136(5):1289-1297. doi: 10.3171/2021.4.JNS21465. Print 2022 May 1.
2
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Hearing Preservation Outcomes in Patients With Sporadic Vestibular Schwannomas.美国神经外科学会关于散发前庭神经鞘瘤患者听力保护结果的系统评价和循证指南
Neurosurgery. 2018 Feb 1;82(2):E35-E39. doi: 10.1093/neuros/nyx511.
3
Translabyrinthine microsurgical resection of small vestibular schwannomas.经迷路显微切除术治疗小型前庭神经鞘瘤。
J Neurosurg. 2018 Jul;129(1):128-136. doi: 10.3171/2017.2.JNS162287. Epub 2017 Aug 18.
4
The Effect of Age on Facial Nerve Recovery After Vestibular Schwannoma Resection.年龄对听神经瘤切除后面神经恢复的影响。
Otol Neurotol. 2023 Aug 1;44(7):725-729. doi: 10.1097/MAO.0000000000003937. Epub 2023 Jul 1.
5
Patient- versus physician-reported facial disability in vestibular schwannoma: an international cross-sectional study.患者与医生报告的前庭神经鞘瘤面部残疾:一项国际横断面研究。
J Neurosurg. 2017 Nov;127(5):1015-1024. doi: 10.3171/2016.8.JNS16707. Epub 2016 Dec 2.
6
Preservation of Hearing and Facial Nerve Function with the Microsurgical Excision of Large Vestibular Schwannomas: Experience with the Retrosigmoid Approach.经乙状窦后入路显微手术切除大型前庭神经鞘瘤时听力和面神经功能的保留:经验总结
Cureus. 2018 Dec 4;10(12):e3684. doi: 10.7759/cureus.3684.
7
A matched cohort comparison of clinical outcomes following microsurgical resection or stereotactic radiosurgery for patients with small- and medium-sized vestibular schwannomas.对接受显微手术切除或立体定向放射外科治疗的小、中型前庭神经鞘瘤患者的临床结局进行配对队列比较。
J Neurosurg. 2016 Dec;125(6):1472-1482. doi: 10.3171/2015.12.JNS151857. Epub 2016 Apr 1.
8
Endoscope-assisted middle fossa craniotomy for resection of inferior vestibular nerve schwannoma extending lateral to transverse crest.内镜辅助中颅窝经横嵴入路切除向外侧延伸的前庭下神经鞘瘤。
Neurosurg Focus. 2018 Mar;44(3):E7. doi: 10.3171/2017.12.FOCUS17663.
9
Efficacy and outcomes of facial nerve-sparing treatment approach to cerebellopontine angle meningiomas.保留面神经的小脑桥脑角脑膜瘤治疗方法的疗效和结果。
J Neurosurg. 2017 Dec;127(6):1231-1241. doi: 10.3171/2016.10.JNS161982. Epub 2017 Feb 10.
10
Microsurgical Management of Vestibular Schwannoma (Acoustic Neuroma): Facial Nerve Outcomes, Radiographic Analysis, Complications, and Long-Term Follow-Up in a Series of 420 Surgeries.显微镜下前庭神经鞘瘤(听神经瘤)的治疗:420 例手术系列中的面神经结果、影像学分析、并发症和长期随访。
World Neurosurg. 2022 Dec;168:e297-e308. doi: 10.1016/j.wneu.2022.09.125. Epub 2022 Oct 2.

引用本文的文献

1
Quality of Life Outcomes in Vestibular Schwannoma: A Prospective Analysis of Treatment Modalities.前庭神经鞘瘤的生活质量结局:治疗方式的前瞻性分析
Laryngoscope. 2025 Jul;135(7):2529-2537. doi: 10.1002/lary.32080. Epub 2025 Feb 27.
2
Dynamic contrast-enhanced and diffusion-weighted MR imaging for predicting tumor growth of sporadic vestibular schwannomas: A prospective study.动态对比增强磁共振成像和扩散加权磁共振成像预测散发性前庭神经鞘瘤的肿瘤生长:一项前瞻性研究。
Neuro Oncol. 2025 May 15;27(4):1116-1127. doi: 10.1093/neuonc/noae252.
3
Quantitative Assessment of Collagen Architecture to Determine Role of Tumor Stroma During Vestibular Schwannoma Progression.
定量评估胶原蛋白结构以确定肿瘤基质在前庭神经鞘瘤进展中的作用。
Otolaryngol Head Neck Surg. 2025 Feb;172(2):614-622. doi: 10.1002/ohn.1018. Epub 2024 Nov 7.
4
Development and application of explainable artificial intelligence using machine learning classification for long-term facial nerve function after vestibular schwannoma surgery.基于机器学习分类的可解释人工智能在前庭神经鞘瘤手术后长期面神经功能中的开发与应用
J Neurooncol. 2025 Jan;171(1):165-177. doi: 10.1007/s11060-024-04844-7. Epub 2024 Oct 11.
5
Correlation of Immunomodulatory Cytokines with Tumor Volume and Cerebrospinal Fluid in Vestibular Schwannoma Patients.前庭神经鞘瘤患者免疫调节细胞因子与肿瘤体积及脑脊液的相关性
Cancers (Basel). 2024 Aug 29;16(17):3002. doi: 10.3390/cancers16173002.
6
Wait-and-scan management in sporadic Koos grade 4 vestibular schwannomas: A longitudinal volumetric study.散发性库斯4级前庭神经鞘瘤的等待观察与扫描管理:一项纵向容积研究
Neurooncol Adv. 2023 Nov 3;6(1):vdad144. doi: 10.1093/noajnl/vdad144. eCollection 2024 Jan-Dec.
7
Evolution in the management of vestibular schwannoma: a single-center 15-year experience.前庭神经鞘瘤治疗的演变:单中心 15 年经验。
Eur Arch Otorhinolaryngol. 2023 Nov;280(11):4885-4894. doi: 10.1007/s00405-023-08009-6. Epub 2023 May 17.
8
Application of Subperineural Resection Technique in Vestibular Schwannomas: Surgical Efficacy and Outcomes in 124 patients.会阴下神经切除术技术在前庭神经鞘瘤中的应用:124例患者的手术疗效及结果
Front Oncol. 2022 Apr 20;12:849109. doi: 10.3389/fonc.2022.849109. eCollection 2022.
9
Long-term natural history and patterns of sporadic vestibular schwannoma growth: A multi-institutional volumetric analysis of 952 patients.长期自然史和散发性前庭神经鞘瘤生长模式:952 例患者的多机构容积分析。
Neuro Oncol. 2022 Aug 1;24(8):1298-1306. doi: 10.1093/neuonc/noab303.